Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 58
Filtrar
1.
Contact Dermatitis ; 84(2): 95-102, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32876992

RESUMEN

BACKGROUND: Studies suggest that patch testing with formaldehyde releasers (FRs) gives significant additional information to formaldehyde 1% aq. and should be considered for addition to the European baseline series (EBS). It is not known if this is also true for formaldehyde 2% aq. OBJECTIVES: To determine the frequency of sensitization to formaldehyde 2% aq. and co-reactivity with FRs. To establish whether there is justification for including FRs in the EBS. MATERIALS AND METHODS: A 4-year, multi-center retrospective analysis of patients with positive patch test reactions to formaldehyde 2% aq. and five FRs. RESULTS: A maximum of 15 067 patients were tested to formaldehyde 2% aq. and at least one FR. The percentage of isolated reactions to FR, without co-reactivity to, formaldehyde 2% aq. for each FR were: 46.8% for quarternium-15 1% pet.; 67.4% imidazolidinyl urea 2% pet.; 64% diazolidinyl urea 2% pet.; 83.3% 1,3-dimethylol-5, 5-dimethyl hydantoin (DMDM) hydantoin 2% pet. and 96.3% 2-bromo-2-nitropropane-1,3-diol 0.5% pet. This demonstrates that co-reactivity varies between FRs and formaldehyde, from being virtually non-existent in 2-bromo-2-nitropropane-1,3-diol 0.5% pet. (Cohen's kappa: 0, 95% confidence interval [CI] -0.02 to 0.02)], to only weak concordance for quaternium-15 [Cohen's kappa: 0.22, 95%CI 0.16 to 0.28)], where Cohen's kappa value of 1 would indicate full concordance. CONCLUSIONS: Formaldehyde 2% aq. is an inadequate screen for contact allergy to the formaldehyde releasers, which should be considered for inclusion in any series dependant on the frequency of reactions to and relevance of each individual allergen.


Asunto(s)
Dermatitis Alérgica por Contacto/diagnóstico , Formaldehído/administración & dosificación , Formaldehído/efectos adversos , Pruebas del Parche/métodos , Alérgenos/administración & dosificación , Alérgenos/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Humanos , Nitroparafinas/administración & dosificación , Nitroparafinas/efectos adversos , Propano/administración & dosificación , Propano/efectos adversos , Propano/análogos & derivados , Urea/administración & dosificación , Urea/efectos adversos , Urea/análogos & derivados
2.
J Appl Toxicol ; 40(5): 691-705, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32030785

RESUMEN

Two proposition 65 no-significant-risk level (NSRL)-type values were derived for 2-nitropropane (2-NP), in the absence of a Californian published NSRL. In addition, a safety assessment was performed based on estimated typical consumer inhalation and dermal exposure to 2-NP during indoor application of paint from a spray can containing the solvent 1-nitropropane. For the NSRL derivation, benchmark dose (BMD) modeling was performed using hepatocellular carcinoma incidence data from 2-NP single exposure inhalation studies in Sprague-Dawley rats. Several BMD models provided an acceptable fit for the male rat hepatocellular carcinoma incidence data (gamma, log-probit, log-logistic and multistage); therefore, the mean of the BMD lower limits from each model were used as the point of departure to derive the inhalation cancer potency. The oral human cancer potency was derived from the inhalation human cancer potency based on the ratio of the uptake factors for inhalation vs. oral routes. The derived inhalation and oral NSRLs are 67 µg/day and 32 µg/day, respectively. For the inhalation and dermal exposure assessment, three key factors were analyzed: the 2-NP residual concentration in the spray paint product, the mass of spray paint used and the frequency of use. Based on the screening exposure assessment, potential consumer inhalation and dermal exposure to 2-NP from indoor application of paint from a spray can does not exceed our proposed NSRLs, and a warning label is therefore not required for spray can products containing the solvent 1-nitropropane where 2-NP is a minor contaminant.


Asunto(s)
Nitroparafinas/toxicidad , Propano/análogos & derivados , Solventes/toxicidad , Administración por Inhalación , Administración Oral , Animales , Humanos , Masculino , Rociadores Nasales , Nitroparafinas/administración & dosificación , Vaporizadores Orales , Propano/administración & dosificación , Propano/toxicidad , Ratas Sprague-Dawley , Medición de Riesgo , Solventes/administración & dosificación , Toxicocinética
3.
Int J Pharm ; 566: 652-661, 2019 Jul 20.
Artículo en Inglés | MEDLINE | ID: mdl-31181308

RESUMEN

Pulmonary delivery is a highly attractive alternative to injections for biologics such as therapeutic proteins. However, bioavailabilities generally suffer from the presence of phagocytic cells that clear particulate matter entering the lung. In this study, microgel particles were developed using an all-aqueous two-phase system approach and evaluated for their efficacy as an inhalable controlled release system. Norbornene- and thiol-modified four- and eight-armed poly (ethylene glycol) with an average molecular mass of 10,000 Da were prepared as macromonomers for microgel formation. Emulsions of precursor solution droplets containing macromonomers and Irgacure 2959 as photocatalyst were prepared in a dextran solution. Irradiation with UV light was used to covalently crosslink the droplets by triggering the thiol-ene reaction. The resulting microgels were processed to dry powder inhaler formulations, and respirable aerodynamic sizes were assessed in vitro. Microgels were loaded with the model proteins lysozyme and bovine serum albumin, with encapsulation efficiencies of 51.5% and 73.6%, respectively. Depending on the macromonomer type, protein-loaded microgels released their cargo over a 6-14 day period. In an MTT assay, the particles did not show significant cytotoxicity, and their recognition by alveolar macrophages was considerably lower than for polystyrene control particles. This makes the microgels a promising pulmonary delivery system for proteins and other biologics.


Asunto(s)
Hidrogeles/administración & dosificación , Microesferas , Muramidasa/administración & dosificación , Polietilenglicoles/administración & dosificación , Albúmina Sérica Bovina/administración & dosificación , Administración por Inhalación , Animales , Línea Celular , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Hidrogeles/química , Pulmón/metabolismo , Macrófagos Alveolares/efectos de los fármacos , Macrófagos Alveolares/metabolismo , Ratones , Muramidasa/química , Fagocitosis , Polietilenglicoles/química , Propano/administración & dosificación , Propano/análogos & derivados , Propano/química , Propano/efectos de la radiación , Albúmina Sérica Bovina/química , Rayos Ultravioleta
4.
Br J Pharmacol ; 173(14): 2290-302, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27160064

RESUMEN

BACKGROUND AND PURPOSE: NO deficiency and oxidative stress are crucially involved in the development or progression of cardiovascular disease, including hypertension and stroke. We have previously demonstrated that acute treatment with the newly discovered organic nitrate, 2-nitrate-1,3-dibuthoxypropan (NDBP), is associated with NO-like effects in the vasculature. This study aimed to further characterize the mechanism(s) and to elucidate the therapeutic potential in a model of hypertension and oxidative stress. EXPERIMENTAL APPROACH: A combination of ex vivo, in vitro and in vivo approaches was used to assess the effects of NDBP on vascular reactivity, NO release, NADPH oxidase activity and in a model of hypertension. KEY RESULTS: Ex vivo vascular studies demonstrated NDBP-mediated vasorelaxation in mesenteric resistance arteries, which was devoid of tolerance. In vitro studies using liver and kidney homogenates revealed dose-dependent and sustained NO generation by NDBP, which was attenuated by the xanthine oxidase inhibitor febuxostat. In addition, NDBP reduced NADPH oxidase activity in the liver and prevented angiotensin II-induced activation of NADPH oxidase in the kidney. In vivo studies showed that NDBP halted the progression of hypertension in mice with chronic angiotensin II infusion. This was associated with attenuated cardiac hypertrophy, and reduced NADPH oxidase-derived oxidative stress and fibrosis in the kidney and heart. CONCLUSION AND IMPLICATIONS: The novel organic nitrate NDBP halts the progression of angiotensin II-mediated hypertension. Mechanistically, our findings suggest that NDBP treatment is associated with sustained NO release and attenuated activity of NADPH oxidase, which to some extent requires functional xanthine oxidase.


Asunto(s)
Angiotensina II/farmacología , Hipertensión/tratamiento farmacológico , Hipertensión/prevención & control , Nitratos/farmacología , Óxido Nítrico/biosíntesis , Estrés Oxidativo/efectos de los fármacos , Propano/análogos & derivados , Angiotensina II/administración & dosificación , Animales , Relación Dosis-Respuesta a Droga , Hipertensión/inducido químicamente , Ratones , Ratones Endogámicos C57BL , NADPH Oxidasas/antagonistas & inhibidores , NADPH Oxidasas/metabolismo , Nitratos/administración & dosificación , Propano/administración & dosificación , Propano/farmacología , Ratas , Ratas Wistar
5.
Bioorg Med Chem ; 24(8): 1589-97, 2016 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-27010500

RESUMEN

A series of N,N-3-phenyl-3-benzylaminopropanamide derivatives were identified as novel CETP (cholesteryl ester transfer protein) inhibitors. In our previous study, lead compound L10 was discovered by pharmacophore-based virtual screening (Dong-Mei Zhao et al., 2014). Based on L10 (IC50 8.06 µM), compound HL6 (IC50 10.7 µM) was discovered following systematic structure variation and biological tests. Further optimization of the structure-activity relationship (SAR) resulted in N,N-3-phenyl-3-benzylaminopro panamides derivatives as novel CETP inhibitors. They were synthesized and evaluated against CETP by BODIPY-CE fluorescence assay. Among them, HL16 (IC50 0.69 µM) was a highly potent CETP inhibitor in vitro. In addition, HL16 exhibited favorable HDL-C enhancement and LDL-C reduction in vivo by hamster. The molecular docking of HL16 into the CETP was performed. The binding mode demonstrated that HL16 occupied the CETP binding site and formed interactions with the key amino acid residues.


Asunto(s)
Bencilaminas/farmacología , Proteínas de Transferencia de Ésteres de Colesterol/antagonistas & inhibidores , Diseño de Fármacos , Propano/análogos & derivados , Administración Oral , Animales , Bencilaminas/administración & dosificación , Bencilaminas/química , Cricetinae , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Simulación del Acoplamiento Molecular , Estructura Molecular , Propano/administración & dosificación , Propano/química , Propano/farmacología , Relación Estructura-Actividad
6.
J Toxicol Sci ; 41(1): 91-104, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26763396

RESUMEN

We previously reported that 28-day exposure to hepatocarcinogens that facilitate cell proliferation specifically alters the expression of G1/S checkpoint-related genes and proteins, induces aberrant early expression of ubiquitin D (UBD) at the G2 phase, and increases apoptosis in the rat liver, indicating G1/S and spindle checkpoint dysfunction. The present study aimed to determine the time of onset of carcinogen-specific cell-cycle disruption after repeated administration of renal carcinogens for up to 28 days. Rats were orally administered the renal carcinogens nitrofurantoin (NFT), 1-amino-2,4-dibromoantraquinone (ADAQ), and 1,2,3-trichloropropane (TCP) or the non-carcinogenic renal toxicants 1-chloro-2-propanol, triamterene, and carboxin for 3, 7 or 28 days. Both immunohistochemical single-molecule analysis and real-time RT-PCR analysis revealed that carcinogen-specific expression changes were not observed after 28 days of administration. However, the renal carcinogens ADAQ and TCP specifically reduced the number of cells expressing phosphorylated-histone H3 at Ser10 in both UBD(+) cells and proliferating cells, suggestive of insufficient UBD expression at the M phase and early transition of proliferating cells from the M phase, without increasing apoptosis, after 28 days of administration. In contrast, NFT, which has marginal carcinogenic potential, did not induce such cellular responses. These results suggest that it may take 28 days to induce spindle checkpoint dysfunction by renal carcinogens; however, induction of apoptosis may not be essential. Thus, induction of spindle checkpoint dysfunction may be dependent on carcinogenic potential of carcinogen examined, and marginal carcinogens may not exert sufficient responses even after 28 days of administration.


Asunto(s)
Antraquinonas/administración & dosificación , Antraquinonas/toxicidad , Riñón/citología , Puntos de Control de la Fase M del Ciclo Celular/efectos de los fármacos , Nitrofurantoína/administración & dosificación , Nitrofurantoína/toxicidad , Propano/análogos & derivados , Animales , Peso Corporal/efectos de los fármacos , Carboxina/administración & dosificación , Carboxina/toxicidad , Proliferación Celular/efectos de los fármacos , Clorhidrinas/administración & dosificación , Clorhidrinas/toxicidad , Histonas/metabolismo , Riñón/efectos de los fármacos , Masculino , Tamaño de los Órganos/efectos de los fármacos , Propano/administración & dosificación , Propano/toxicidad , Ratas Endogámicas F344 , Factores de Tiempo , Triantereno/administración & dosificación , Triantereno/toxicidad , Ubiquitinas/metabolismo
7.
Toxicol Ind Health ; 32(9): 1589-97, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25681370

RESUMEN

1,2-Dichloropropane (1,2-DCP), a solvent, which is the main component of the cleaner used in the offset printing companies in Japan, is suspected to be the causative agent of bile duct cancer, which has been recently reported at high incidence in those offset printing workplaces. While there are some reports about the acute toxicity of 1,2-DCP, no information about its metabolism related to toxicity in animals is available. As part of our efforts toward clarifying the role of 1,2-DCP in the development of cancer, we studied the metabolic pathways and the hepatotoxic effect of 1,2-DCP in mice with or without cytochrome P450 2E1 (CYP2E1) activity. In an in vitro reaction system containing liver homogenate, 1,2-DCP was only metabolized by liver tissue of wild-type mice but not by that of cyp2e1-null mice. Furthermore, the kinetics of the solvent in mice revealed a great difference between the two genotypes; 1,2-DCP administration resulted in dose-dependent hepatic damage, as shown biochemically and pathologically, but this effect was only observed in wild-type mice. The nuclear factor κB p52 pathway was involved in the liver response to 1,2-DCP. Our results clearly indicate that the oxidative metabolism of 1,2-DCP in mice is exclusively catalyzed by CYP2E1, and this step is indispensable for the manifestation of the hepatotoxic effect of the solvent.


Asunto(s)
Carcinógenos Ambientales/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/enzimología , Citocromo P-450 CYP2E1/metabolismo , Hígado/metabolismo , Propano/análogos & derivados , Solventes/metabolismo , Activación Metabólica , Transporte Activo de Núcleo Celular/efectos de los fármacos , Animales , Animales no Consanguíneos , Carcinógenos Ambientales/administración & dosificación , Carcinógenos Ambientales/análisis , Carcinógenos Ambientales/toxicidad , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Citocromo P-450 CYP2E1/genética , Relación Dosis-Respuesta a Droga , Inyecciones Intraperitoneales , Insecticidas/administración & dosificación , Insecticidas/sangre , Insecticidas/metabolismo , Insecticidas/toxicidad , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Ratones , Ratones de la Cepa 129 , Ratones Noqueados , Subunidad p52 de NF-kappa B/metabolismo , Oxidación-Reducción , Propano/administración & dosificación , Propano/sangre , Propano/metabolismo , Propano/toxicidad , Solventes/administración & dosificación , Solventes/análisis , Solventes/toxicidad , Toxicocinética
8.
Mol Cancer Ther ; 14(11): 2623-33, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26358750

RESUMEN

Hepatocellular carcinoma (HCC) can arise from chronic inflammation due to viral infection, organ damage, drug toxicity, or alcohol abuse. Moreover, gene desensitization via aberrant CpG island methylation is a frequent epigenetic defect in HCC. However, the details of how inflammation is linked with epigenetic-mediated desensitization of tumor suppressor genes remains less investigated. In this study, we found that loss of CEBPD enhances the growth of liver cancer cells and is associated with the occurrence of liver cancers, as determined by the assessment of clinical specimens and in vivo animal models. Moreover, E2F1-regulated epigenetic axis attenuated CEBPD expression in liver cancer cells. CEBPD is responsive to the hydroxymethyldibenzoylmethane (HMDB)-induced p38/CREB pathway and plays an important role in the HMDB-induced apoptosis of cancer cells. Regarding depression of epigenetic effects to enhance HMDB-induced CEBPD expression, the combination of HMDB and 5-Aza-2'-deoxycytidine (5-AzadC) could enhance the death of liver cancer cells and reduce the tumor formation of Huh7 xenograft mice. In conclusion, these results suggest that CEBPD could be a useful diagnostic marker and therapeutic target in HCC. The results also reveal the therapeutic potential for low-dose 5-AzadC to enhance the HMDB-induced death of HCC cells.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Azacitidina/análogos & derivados , Proteína delta de Unión al Potenciador CCAAT/antagonistas & inhibidores , Carcinoma Hepatocelular/tratamiento farmacológico , Cetonas/farmacología , Neoplasias Hepáticas/tratamiento farmacológico , Propano/análogos & derivados , Animales , Apoptosis/efectos de los fármacos , Apoptosis/genética , Azacitidina/administración & dosificación , Azacitidina/farmacología , Western Blotting , Proteína delta de Unión al Potenciador CCAAT/genética , Proteína delta de Unión al Potenciador CCAAT/metabolismo , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/metabolismo , Línea Celular Tumoral , Células Cultivadas , Decitabina , Factor de Transcripción E2F1/genética , Factor de Transcripción E2F1/metabolismo , Perfilación de la Expresión Génica/métodos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Células Hep G2 , Humanos , Inmunohistoquímica , Cetonas/administración & dosificación , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/metabolismo , Ratones Endogámicos NOD , Ratones SCID , Análisis de Secuencia por Matrices de Oligonucleótidos , Propano/administración & dosificación , Propano/farmacología , Interferencia de ARN , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Carga Tumoral/efectos de los fármacos , Carga Tumoral/genética , Ensayos Antitumor por Modelo de Xenoinjerto
9.
Ugeskr Laeger ; 177(2)2015 Jan 05.
Artículo en Danés | MEDLINE | ID: mdl-25557449

RESUMEN

We describe a case report of a 23-year-old man with acute pharyngeal injuries due to frostbite subsequent to inhalation of propane. He was fiber-optically intubated on admission to hospital since his airways were considered acutely compromised. He was subsequently kept intubated for 11 days due to persistent pharyngeal oedema and frostbite injuries. The latter is caused by low temperature of propane upon release from a pressurized container. Injuries caused by frostbite often gradually progress and thus caution should be exerted in regards to airway management.


Asunto(s)
Quemaduras por Inhalación/complicaciones , Congelación de Extremidades/inducido químicamente , Propano/efectos adversos , Quemaduras por Inhalación/patología , Congelación de Extremidades/patología , Humanos , Intubación Intratraqueal , Masculino , Boca/lesiones , Boca/patología , Faringe/lesiones , Faringe/patología , Propano/administración & dosificación , Adulto Joven
10.
Auton Neurosci ; 181: 31-6, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24418115

RESUMEN

The search for new nitric oxide donors is warranted by the limitations of organic nitrates currently used in cardiology. The new organic nitrate 2-nitrate-1,3-dibuthoxypropan (NDBP) exhibited promising cardiovascular activities in previous studies. The aim of this study was to investigate the cardiorespiratory responses evoked by NDBP and to compare them to the clinically used organic nitrate nitroglycerine (NTG). Arterial pressure, heart rate and respiration were recorded in conscious adult male Wistar rats. Bolus i.v. injection of NDBP (1 to 15mg/kg; n=8) and NTG (0.1 to 5mg/kg; n=8) produced hypotension. NDBP induced bradycardia at all doses, while NTG induced tachycardia at three lower doses but bradycardia at higher doses. Hydroxocobalamin (20mg/kg; HDX), a NO scavenger, blunted hypotension induced by NDBP (15mg/kg), and its bradycardic effect (n=6). In addition, HDX blunted both hypotension and bradycardia induced by a single dose of NTG (2.5mg/kg; n=6). Both NDBP and NTG altered respiratory rate, inducing a biphasic effect with a bradypnea followed by a tachypnea; HDX attenuated these responses. Our data indicate that NDBP and NTG induce hypotension, bradycardia and bradypnea, which are mediated by nitric oxide release.


Asunto(s)
Presión Arterial/efectos de los fármacos , Fármacos Cardiovasculares/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Nitratos/farmacología , Propano/análogos & derivados , Respiración/efectos de los fármacos , Animales , Presión Arterial/fisiología , Bradicardia/inducido químicamente , Bradicardia/tratamiento farmacológico , Bradicardia/fisiopatología , Fármacos Cardiovasculares/administración & dosificación , Estado de Conciencia , Relación Dosis-Respuesta a Droga , Frecuencia Cardíaca/fisiología , Hidroxocobalamina/farmacología , Hipotensión/inducido químicamente , Hipotensión/tratamiento farmacológico , Hipotensión/fisiopatología , Masculino , Nitratos/administración & dosificación , Óxido Nítrico/metabolismo , Nitroglicerina/administración & dosificación , Nitroglicerina/farmacología , Propano/administración & dosificación , Propano/farmacología , Ratas , Ratas Wistar , Taquipnea/inducido químicamente , Taquipnea/tratamiento farmacológico , Taquipnea/fisiopatología , Vasodilatadores/administración & dosificación , Vasodilatadores/farmacología
11.
Artículo en Inglés | MEDLINE | ID: mdl-23364888

RESUMEN

Although histopathology is considered the gold standard for assessing testicular toxicity in the nonclinical setting, identification of noninvasive biomarkers for testicular injury are desirable to improve safety monitoring capabilities for clinical trials. Inhibin B has been investigated as a noninvasive biomarker for testicular toxicity. This study investigates the correlation of Inhibin B in Wistar Han rats with the onset and reversibility of testicular histopathology from classical testicular toxicants carbendazim, cetrorelix acetate (CTX), and 1,2-dibromo-3-chloropropane (DBCP). The dose regimen included Interim (day 8), Drug (day 29), and nondosing Recovery (day 58) Phases. Inhibin B was not effective at predicting the onset of carbendazim- or CTX-mediated testicular pathology in rats. Inhibin B was reduced by DBCP administration at the end of the Drug Phase only, acting as a leading indicator of the onset of testicular toxicity before the onset of germ cell depletion. However, since Inhibin B was only decreased at the end of the Dosing Phase and not at the Recovery Phase, when the onset of testicular pathology occurred, it is unclear if monitoring Inhibin B would provide sufficient advanced warning for the onset of testicular pathology. Furthermore, follicle stimulating hormone was decreased following CTX and DBCP administration in the Interim Phase and CTX in the Drug Phase. Inhibin B has limited predictive capacity as a leading testicular biomarker in rats.


Asunto(s)
Bencimidazoles/toxicidad , Carbamatos/toxicidad , Hormona Liberadora de Gonadotropina/análogos & derivados , Inhibinas/sangre , Propano/análogos & derivados , Testículo/patología , Animales , Bencimidazoles/administración & dosificación , Biomarcadores/sangre , Peso Corporal/efectos de los fármacos , Carbamatos/administración & dosificación , Hormona Folículo Estimulante/sangre , Hormona Liberadora de Gonadotropina/administración & dosificación , Hormona Liberadora de Gonadotropina/toxicidad , Hormona Luteinizante/sangre , Masculino , Tamaño de los Órganos/efectos de los fármacos , Propano/administración & dosificación , Propano/toxicidad , Ratas , Ratas Wistar , Análisis de Supervivencia , Testículo/efectos de los fármacos , Testículo/metabolismo
12.
J Craniomaxillofac Surg ; 40(8): e342-5, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22421467

RESUMEN

This study evaluated the results of curettage followed by spray propane, butane, and isobutane gas combination cryosurgery in 10 patients with ameloblastoma. The patients' age ranged from 7 to 87 years (mean, 31 years), with equal prevalence in both men and women. Five cases were diagnosed as solid ameloblastomas and 5 as unicystic ameloblastomas. Before enucleation and cryosurgery, the unicystic lesions received marsupialisation to decrease their size. No patient showed evidence of clinical or radiographic recurrence, pathologic fracture, or infection after treatment with enucleation and cryosurgery. The most common complication was wound dehiscence, which was observed in all cases. The average follow-up period was 60.5 months (range 48-108 months). These results show that enucleation followed by cryosurgery is an effective therapy for managing ameloblastomas.


Asunto(s)
Ameloblastoma/cirugía , Criocirugía/métodos , Neoplasias Mandibulares/cirugía , Adolescente , Adulto , Anciano de 80 o más Años , Butanos/administración & dosificación , Niño , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Propano/administración & dosificación , Estudios Retrospectivos , Dehiscencia de la Herida Operatoria/etiología , Adulto Joven
13.
J Chromatogr B Analyt Technol Biomed Life Sci ; 879(31): 3763-6, 2011 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-22055830

RESUMEN

UP302 is a novel natural antioxidant isolated from Dianella ensifolia (Liliaceae). In the investigation, a specific and sensitive ultra-high performance liquid chromatography-tandem mass spectrometry for quantitative determination of UP302 in rat plasma was developed and validated. UP302 and the internal standard daidzein were extracted from 100 µL aliquots of rat plasma using methanol. Detection of UP302 and IS was done by tandem mass spectrometry, operating in negative ion and selected reaction monitoring acquisition mode. The precursor-product ion transitions monitored for UP302 and daidzein were m/z 301.1→135.2 and 252.9→132.0, respectively. The linearity of the method was observed within the concentration range of 5-2000 ng/mL. Intra- and inter-day assay variations were less than 15%, and the accuracy values were between 99.2% and 107.3%. The method was successfully applied to stability investigation of UP302 incubated in rat plasma at 37°C and measurement of UP302 in plasma after intravenous administration of UP302 to rats at a single dose of 5 mg/kg. Incubation stability revealed that within first one hour, UP302 was rapidly declined approximately 35% and remained stable after 4 h. Pharmacokinetic values of half-life, volume of distribution, systemic clearance and mean residence time were 0.87 ± 0.58 h, 6.90 ± 3.35 L/kg, 5.89 ± 1.21 L/h kg and 0.34 ± 0.13 h, respectively.


Asunto(s)
Antioxidantes/análisis , Cromatografía Líquida de Alta Presión/métodos , Fenoles/sangre , Propano/análogos & derivados , Espectrometría de Masas en Tándem/métodos , Animales , Antioxidantes/administración & dosificación , Antioxidantes/farmacocinética , Estabilidad de Medicamentos , Liliaceae/química , Límite de Detección , Masculino , Fenoles/administración & dosificación , Fenoles/farmacocinética , Propano/administración & dosificación , Propano/sangre , Propano/farmacocinética , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Temperatura
14.
Contact Dermatitis ; 62(1): 18-31, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20136876

RESUMEN

This is the second part of an article on formaldehyde-releasers in cosmetics. The patch test relationship between the releasers in cosmetics to formaldehyde contact allergy is reviewed and it is assessed whether products preserved with formaldehyde-releasers may contain enough free formaldehyde to pose a threat to individuals with contact allergy to formaldehyde. There is a clear relationship between positive patch test reactions to formaldehyde-releasers and formaldehyde contact allergy: 15% of all reactions to 2-bromo-2-nitropropane-1,3-diol and 40-60% of the reactions to the other releasers are caused by a reaction to the formaldehyde in the test material. There is only fragmented data on the amount of free formaldehyde in cosmetics preserved with formaldehyde donors. However, all releasers (with the exception of 2-bromo-2-nitropropane-1,3-diol, for which adequate data are lacking) can, in the right circumstances of concentration and product composition, release >200 p.p.m. formaldehyde, which may result in allergic contact dermatitis. Whether this is actually the case in any particular product cannot be determined from the ingredient labelling. Therefore, we recommend advising patients allergic to formaldehyde to avoid leave-on cosmetics preserved with quaternium-15, diazolidinyl urea, DMDM hydantoin, or imidazolidinyl urea, acknowledging that many would tolerate some products.


Asunto(s)
Cosméticos/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Formaldehído/efectos adversos , Cosméticos/administración & dosificación , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/epidemiología , Dioxanos/efectos adversos , Europa (Continente)/epidemiología , Formaldehído/administración & dosificación , Humanos , Hidantoínas/administración & dosificación , Hidantoínas/efectos adversos , Metanol/efectos adversos , Metanol/análogos & derivados , Metenamina/administración & dosificación , Metenamina/efectos adversos , Metenamina/análogos & derivados , Éteres Metílicos/efectos adversos , Nitroparafinas/administración & dosificación , Nitroparafinas/efectos adversos , Pruebas del Parche , Propano/administración & dosificación , Propano/efectos adversos , Propano/análogos & derivados , Riesgo , Estados Unidos/epidemiología , Urea/administración & dosificación , Urea/efectos adversos , Urea/análogos & derivados
15.
Eur J Pharmacol ; 595(1-3): 22-9, 2008 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-18706410

RESUMEN

We previously reported the synthesis of three new opioid agonists as well as their in vitro and in vivo activity [Girón, R., Abalo, R., Goicoechea, C., Martín, M.I., Callado, L.F., Cano, C., Goya, P., Jagerovic, N. 2002. Synthesis and opioid activity of new fentanyl analogs. Life Sci. 71, 1023-1034]. One of them, N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl)] propenamide (IQMF-4), showed an interesting antinociceptive activity. Intraperitoneally (i.p.) administered, it was as effective as fentanyl or morphine, being less potent than fentanyl but more so than morphine. The aim of the present work was to evaluate its antinociceptive effect by different routes of administration, using the hot plate test, and to investigate possible side effects, such as tolerance and withdrawal, in vitro, using the myenteric plexus-longitudinal muscle strip preparation from guinea pig ileum, and in vivo, using the hot plate test. IQMF-4 was more potent than morphine when administered per os (p.o.), but less potent when administered intracerebroventricularly (i.c.v.). By both routes, fentanyl is more potent that IQMF-4. When IQMF-4 was administered i.p., naloxone methiodide, a peripherally acting antagonist, was able to completely block its antinociceptive effect, whereas, after i.c.v. administration, the blockade was only partial. An interesting feature of the new compound is that it induces tolerance in vitro but not in vivo. Moreover, though in vitro withdrawal was not different from fentanyl or morphine, in vivo withdrawal symptoms were significantly less frequent in mice treated with IQMF-4 than in those treated with morphine or fentanyl. Although more assays are required, these results show that IQMF-4 appears to be a potent analgesic compound with an interesting peripheral component, and reduced ability to induce dependence.


Asunto(s)
Analgésicos Opioides/farmacología , Umbral del Dolor/efectos de los fármacos , Dolor/prevención & control , Administración Oral , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/efectos adversos , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Tolerancia a Medicamentos , Fentanilo/farmacología , Cobayas , Calor , Íleon/efectos de los fármacos , Íleon/inervación , Inyecciones Intraperitoneales , Inyecciones Intraventriculares , Masculino , Ratones , Morfina/farmacología , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Músculo Liso/inervación , Naloxona/análogos & derivados , Naloxona/farmacología , Antagonistas de Narcóticos/farmacología , Trastornos Relacionados con Opioides/etiología , Trastornos Relacionados con Opioides/prevención & control , Dolor/etiología , Dolor/fisiopatología , Dimensión del Dolor , Piperidinas/administración & dosificación , Piperidinas/efectos adversos , Piperidinas/farmacología , Propano/administración & dosificación , Propano/efectos adversos , Propano/análogos & derivados , Propano/farmacología , Compuestos de Amonio Cuaternario/farmacología , Tiempo de Reacción/efectos de los fármacos , Síndrome de Abstinencia a Sustancias/etiología , Síndrome de Abstinencia a Sustancias/prevención & control , Factores de Tiempo
16.
N Z Med J ; 119(1233): U1952, 2006 May 05.
Artículo en Inglés | MEDLINE | ID: mdl-16680169

RESUMEN

AIM: To describe patterns of inhalant abuse in New Zealand and discuss management. METHODS: Calls to the National Poisons Centre (NPC) from January 1 2003 to December 31 2004 were analysed. In addition, deaths following inhalational abuse were identified from the Institute of Environmental Science and Research Limited (ESR) database for 2001 and 2002 and available data for 2003. RESULTS: Seventy calls were classified as relating to inhalational abuse incidents. In abusers whose age was known, 83% were between 11 and 20 years, and 61% were male. Over half (44/70) of the calls involved abuse of propane or butane, either alone or in combination with a synthetic pyrethroid. ESR coronial data identified 11 inhalant abuse related deaths, most commonly attributed to cardiac effects. 73% of deaths were in teenagers and all but one fatality involved propane and/or butane. CONCLUSIONS: Inhalant abuse is a persisting problem in New Zealand. NPC and ESR data demonstrate that teenagers are more likely to abuse inhalants than other age groups and butane and propane are the inhalants of choice. Acute management can be difficult, with significant mortality and morbidity. Continued education and other preventive measures are essential to help curb an extremely dangerous practice.


Asunto(s)
Administración por Inhalación , Drogas Ilícitas , Trastornos Relacionados con Sustancias/epidemiología , Adolescente , Adulto , Distribución por Edad , Butanos/administración & dosificación , Butanos/envenenamiento , Causas de Muerte , Niño , Femenino , Gasolina/envenenamiento , Humanos , Hidrocarburos/administración & dosificación , Hidrocarburos/envenenamiento , Masculino , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Centros de Control de Intoxicaciones/estadística & datos numéricos , Propano/administración & dosificación , Propano/envenenamiento , Distribución por Sexo , Trastornos Relacionados con Sustancias/mortalidad
17.
Am J Forensic Med Pathol ; 26(4): 355-9, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16304471

RESUMEN

We present a case of an accidental autoerotic death involving the inhalation of a propane-butane gas mixture, also known as LPG (liquefied petroleum gas). A 19-year-old male was found dead in supine position in his bed in a residential accommodation one day after he was last seen alive. On a personal computer at the end of the bed, a pornographic movie was still running. On his left shoulder, an empty rubber balloon and on the bedside 2 empty "Kisag-Gas" cartridges were found. Toxicologic investigations revealed an intoxication with propane and butane, together with a recent consumption of cannabis. This case report compares the toxicologic findings with other recently published cases, and the theories of the toxic effects are discussed.


Asunto(s)
Accidentes , Butanos/envenenamiento , Trastornos Parafílicos , Propano/envenenamiento , Administración por Inhalación , Adulto , Butanos/administración & dosificación , Butanos/farmacocinética , Cromatografía de Gases y Espectrometría de Masas , Humanos , Masculino , Abuso de Marihuana/complicaciones , Propano/administración & dosificación , Propano/farmacocinética , Distribución Tisular
18.
Am J Drug Alcohol Abuse ; 30(1): 155-65, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15083559

RESUMEN

Volatile substance abuse (VSA) is believed to be widespread. The Toxic Exposure Surveillance System (TESS) of the American Association of Poison Control Systems offers an opportunity to evaluate the epidemiology of volatile substance abuse using a data set that captures data from a large geographic area covering a wide-ranging group of socioeconomic strata, ethnic groups, and demographics. To utilize this potential we analyzed a data set of TESS for the 6-year period of 1996 through 2001 involving all cases of intentional inhalational abuse of nonpharmaceutical substances. Over the study period there was a mean annual decline of 9% of reported VSA with an overall decline of 37% from 1996 to 2001. Volatile substance abuse was reported primarily in children, with 6358 cases (54%) in children 13-19 yr and 1803 (15%) cases in children 6-12 yr. Fifty-two cases were reported in children < 5 or = 5 yr. A total of 2330 (20%) VSA cases had a serious outcome, defined as either moderate effect (n = 2000), major effect (n = 267), or death (n = 63). The top five categories of substances abused were gasoline (41%), paint (13%), propane/butane (6%), air fresheners (6%), and formalin (5%). Three categories were responsible for the majority of deaths: gasoline (45%), air fresheners (26%), and propane/butane (11%). While there was a decline in reported cases, there was no decline in major outcomes or fatalities. Volatile substance abuse was reported in all 50 states, with case distribution similar to population distribution. However, seven states had > 2 times the expected rate based on their population; three western states, two midwestern states, and two Appalachian states. The role of urban vs. rural population may possibly explain the difference in numbers, with a greater incidence of VSA cases reported in states with large rural populations. The mean monthly occurrence rate was 162 VSA cases/month (S.D. +/- 10.85). There were 4 months that were > 2 standard deviations from the mean, with two peak months (May, 192/month and March, 187/month) and two trough months (December, 126/month and January, 137/month). This report presents a broad picture of VSA in the United States. Volatile substance abuse, as reported to U.S. poison centers, appears to be on the decline, but continues to be an ongoing problem. Volatile substance abuse is reported throughout the U.S. in all areas of the country, with a higher incidence in states with large rural populations. A small group of substances appears responsible for the majority of deaths. It is imperative that we continue to educate the public and healthcare professionals regarding the risks of VSA and hopefully impact the incidence of VSA.


Asunto(s)
Aerosoles/toxicidad , Centros de Control de Intoxicaciones/estadística & datos numéricos , Informática en Salud Pública , Trastornos Relacionados con Sustancias/epidemiología , Administración por Inhalación , Adolescente , Adulto , Aerosoles/administración & dosificación , Aerosoles/química , Aerosoles/clasificación , Distribución por Edad , Niño , Bases de Datos Factuales , Femenino , Formaldehído/administración & dosificación , Formaldehído/toxicidad , Gasolina/toxicidad , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Pintura/toxicidad , Vigilancia de la Población , Propano/administración & dosificación , Propano/toxicidad , Trastornos Relacionados con Sustancias/clasificación , Tiempo , Estados Unidos/epidemiología
19.
Toxicol Sci ; 76(2): 418-26, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14514963

RESUMEN

The exposure of men to the nematocide dibromochloropropane (DBCP) has caused prolonged oligo- and azoospermia, which occasionally reverses spontaneously. We recently demonstrated that in testes of rats treated with a dose of DBCP sufficient to reduce the percentage of tubules producing differentiating germ cells (tubule differentiation index, TDI) to 20%, the tubules lacking differentiating cells contained type A spermatogonia. To determine whether these type A spermatogonia could be stimulated to differentiate, as had been demonstrated previously in other models of toxicant-induced sterility, we suppressed intratesticular testosterone and serum follicle stimulating hormone (FSH) levels with the GnRH agonist Lupron (leuprolide). When the GnRH agonist was given for 10 weeks starting immediately after DBCP exposure, the TDI was maintained at 94%. Even when GnRH-agonist treatment was stopped at week 10, the TDI remained between 65 and 80% 10 weeks later. Late spermatid counts averaged 10 x 10(6) per testis for the GnRH-agonist-treated rats at week 20 compared with 1.7 x 10(6) per testis in rats treated with only DBCP. To determine whether spermatogonial differentiation could be stimulated after the TDI had declined to below 30%, we initiated GnRH-agonist treatment 6 weeks after DBCP exposure. The GnRH treatment increased the TDI to 53% at week 16. These results indicate that, if the same principles apply to humans, suppression of testosterone may be applied to restore spermatogenesis in men rendered azoospermic by DBCP or other reproductive toxicants.


Asunto(s)
Antinematodos/toxicidad , Leuprolida/uso terapéutico , Oligospermia/tratamiento farmacológico , Propano/análogos & derivados , Propano/toxicidad , Espermatogénesis/efectos de los fármacos , Testículo/efectos de los fármacos , Animales , Antinematodos/administración & dosificación , Femenino , Hormona Folículo Estimulante/sangre , Hormona Liberadora de Gonadotropina/agonistas , Hormona Liberadora de Gonadotropina/sangre , Inyecciones Subcutáneas , Masculino , Propano/administración & dosificación , Ratas , Ratas Sprague-Dawley , Recuperación de la Función/efectos de los fármacos , Recuento de Espermatozoides , Espermátides/efectos de los fármacos , Espermátides/patología , Espermatogénesis/fisiología , Espermatogonias/efectos de los fármacos , Espermatogonias/patología , Testículo/metabolismo , Testículo/patología
20.
Eur J Emerg Med ; 10(1): 44-6, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12637862

RESUMEN

A very rare case of non-fatal acute massive rhabdomyolysis caused by unintentional prolonged inhalation of liquid gas (consisting of butane and propane) in a previously healthy adult is presented. The immediate diagnosis and intensive symptomatic therapy prevented any other severe complications of rhabdomyolysis, and the patient made a complete recovery without any sequelae.


Asunto(s)
Alcanos/envenenamiento , Alquenos/envenenamiento , Gases/efectos adversos , Exposición por Inhalación/efectos adversos , Rabdomiólisis/inducido químicamente , Accidentes Domésticos , Enfermedad Aguda , Adulto , Alcanos/administración & dosificación , Alquenos/administración & dosificación , Butanos/administración & dosificación , Butanos/envenenamiento , Exposición a Riesgos Ambientales/efectos adversos , Gases/administración & dosificación , Humanos , Infusiones Intravenosas , Masculino , Propano/administración & dosificación , Propano/envenenamiento , Rabdomiólisis/diagnóstico , Rabdomiólisis/terapia , Cloruro de Sodio/administración & dosificación , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...